Biopsy News and Research

RSS

Biopsy is the removal of cells or tissues for examination by a pathologist. The pathologist may study the tissue under a microscope or perform other tests on the cells or tissue. There are many different types of biopsy procedures. The most common types include: (1) incisional biopsy, in which only a sample of tissue is removed; (2) excisional biopsy, in which an entire lump or suspicious area is removed; and (3) needle biopsy, in which a sample of tissue or fluid is removed with a needle. When a wide needle is used, the procedure is called a core biopsy. When a thin needle is used, the procedure is called a fine-needle aspiration biopsy.

Study may help develop effective biosensors for non-invasive diagnosis of prostate cancer

The efficacy of biosensors used in clinical tests depends critically on the surface of the device on which the biorecognition molecules are immobilized.

23 Mar 2021

Novel technology may reveal the brain's mysteries

A team of scientists, led by researchers at Northwestern University, Shirley Ryan AbilityLab and the University of Illinois at Chicago (UIC), has developed novel technology promising to increase understanding of how brains develop, and offer answers on repairing brains in the wake of neurotrauma and neurodegenerative diseases.

22 Mar 2021

Weight loss induced by diet and bariatric surgery has different impact on mitochondria in fat tissue

Dieting impairs the energy-producing machinery of fat tissue, potentially resulting in weight regain. In contrast, as indicated by a recently completed European study coordinated by the University of Helsinki, weight loss surgery gives a boost to mitochondria, improving the gene expression of these cellular engines.

18 Mar 2021

AI-based technique determines cancer cells by their acidity

Healthy and cancer cells can look similar under a microscope. One way of differentiating them is by examining the level of acidity, or pH level, inside the cells.

17 Mar 2021

Machine learning approach can identify cancerous single cells by detecting its pH

Cancerous cells exhibit several key differences from healthy cells that help identify them as dangerous. For instance, the pH -- the level of acidity -- within a cancerous cell is not the same as the pH within a healthy cell.

16 Mar 2021

Simple blood test using nanoparticles could enable earlier detection of acute liver damage

University of Texas at Dallas chemist Dr. Jie Zheng has spent much of his career investigating gold nanoparticles for their potential impact in the field of nanomedicine.

10 Mar 2021

Bruker announces new results in deep, unbiased plasma proteomics, PaSER 1.1 software and new cross-linking consumables at US HUPO 2021

At the virtual 17th US HUPO Conference (US HUPO 2021), Bruker Corporation (Nasdaq: BRKR) today announces progress with several collaborations in deep, unbiased plasma proteomics, leveraging the speed, sensitivity and dynamic range of 4D proteomics on timsTOF Pro systems.

From Bruker Daltonics 9 Mar 2021

Immune cells in cerebrospinal fluid could be novel biomarkers of response to immune-based therapies

Results from a study led by Joan Seoane, Director of Preclinical and Translational Research co-program at VHIO and ICREA Professor, show that immune cells accessing cerebrospinal fluid faithfully recapitulate the characteristics of cells identified in brain metastasis, and could therefore constitute novel biomarkers of response to immune-based therapies.

8 Mar 2021

Study proposes a new, noninvasive way to detect kidney transplant rejection

Patients can spend up to six years waiting for a kidney transplant. Even when they do receive a transplant, up to 20 percent of patients will experience rejection.

5 Mar 2021

Newly identified biomarker could predict response to immune checkpoint inhibitors

A team of Roswell Park Comprehensive Cancer Center researchers has identified a new biomarker that could predict response to immune checkpoint inhibitors (ICI) shortly after patients with non-small cell lung cancer (NSCLC) initiate therapy.

3 Mar 2021

Study: Bitter plant compound reduces inflammatory markers

Resveratrol is a plant compound found primarily in red grapes and Japanese knotweed. Its synthetic variant has been approved as a food ingredient in the EU since 2016.

3 Mar 2021

Researchers confirm a threshold value for non-invasive imaging biomarker

Breast cancer is the commonest fatal cancer in women. Early detection increases a woman's chances of recovery. Magnetic Resonance Imaging (MRI) is an accurate technique for detecting and classifying tumors in breast tissue.

2 Mar 2021

New biomarker discovery could help guide treatment of active sarcoidosis

Low blood levels of immune cells called lymphocytes, in combination with higher levels of inflammation on PET/CT scans, are indicators of active sarcoidosis -- an inflammatory disease that attacks multiple organs, particularly the lungs and lymph nodes -- which disproportionately affects African Americans.

25 Feb 2021

Long-term steroid treatment may not be necessary for kidney transplant patients

Long-term use of a medication used to treat kidney transplant patients may not be necessary in individuals with low-to-moderate risk of organ rejection, according to the results of a study led by a University of Cincinnati transplant researcher.

24 Feb 2021

A promising strategy to improve functional capacity of damaged muscle

Muscle is the largest organ that accounts for 40% of body mass and plays an essential role in maintaining our lives.

21 Feb 2021

Highly sensitive blood test for cancer wins 2021 Top 10 Clinical Research Achievement Award

Cancer biologists at Weill Cornell Medicine have been awarded a 2021 Top 10 Clinical Research Achievement Award from the Clinical Research Forum for their study last year describing a highly sensitive blood test for monitoring cancer progression and relapse.

20 Feb 2021

Combination therapy produces clinical benefit for early stage non-small cell lung cancer

The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory.

18 Feb 2021

Biopsy News and Research

Further Reading